Hormone tablets alone gave older women with hormone-sensitive breast cancer similar survival to surgery, a review of 29 studies has found. Surgery controlled the tumour in the breast better, so frailty, tumour biology and each woman's priorities should guide the choice.
Content note: this article discusses breast cancer treatment and survival.
What the review found
Researchers at the University of Pittsburgh and Harvard Medical School pooled data on 22,821 women aged 65 and over. All had early, operable breast cancer that responds to oestrogen, and their median age was 83. Their systematic review and meta-analysis, published in JAMA Network Open on 6 November, compared primary endocrine therapy with surgery. Primary endocrine therapy means hormone-blocking tablets, such as tamoxifen or an aromatase inhibitor, taken without an operation.
Across six randomised trials, overall survival did not differ significantly between the two approaches. Women on tablets alone had a 14% higher risk of dying during follow-up than women who had surgery (hazard ratio 1.14). The 95% confidence interval ran from 2% lower to 33% higher, so the difference could be down to chance. The result also changed depending on which single study was left out.
Deaths from breast cancer showed no significant difference either.
Surgery gave better control of the cancer in the breast across the trials. In one long-running Nottingham trial, local recurrence reached 38% at five years and 43% at ten years, with most cases occurring early. Between 39% and 49% of women whose cancer progressed on tablets in the older trials went on to have surgery.
More of the women died of other causes than of breast cancer. In the trials, 28.8% died of breast cancer and 47.3% of other causes. In the observational studies, the figures were 12.2% and 36.5%.
Why surgery is harder for women in their 80s
Death soon after breast cancer surgery is rare, including in older women. An analysis of 100,037 women in a US surgical quality database was published in Breast Cancer Research and Treatment in 2018. It found that 0.2% of women aged 70 and over died within 30 days, against 0.05% of women aged 40 to 69. Older women had higher rates of heart, lung, clotting and neurological complications, although their overall complication rate was similar.
Delirium after surgery is one of the most serious risks for the very old. A US study of 560 adults aged 70 and over was published in JAMA Internal Medicine in June. It linked delirium after elective surgery to faster cognitive decline for up to five years.
The UK Bridging the Age Gap study followed 3,416 women over 70 from 56 breast units, with a median age of 77. In a matched analysis, mastectomy or removal of the armpit lymph nodes hit quality of life harder than tablets in the first months. By 24 months, most of those effects had resolved. The authors say women considering surgery should be told about them.
Why surgeons and families hold back
Surgeons are often reluctant to put very old women through an operation, and some of that caution reflects clinical judgement. University of Manchester researchers interviewed 28 women over 70 who were taking tablets in place of surgery, in a 2015 study in Psycho-Oncology. Some had declined surgery themselves. For others, the surgeon had decided that their other health conditions ruled an operation out.
A 2024 review in Psycho-Oncology found that families shape these decisions too. It brought together 13 studies of 1,118 older women with operable breast cancer. The experiences of friends and relatives who had been through cancer treatment influenced some women. In one study, a relative's bad experience was the only factor some women cited.
Women in the review also said they wanted to stay independent and avoid being a burden on others. Many relied on relatives to get them to appointments, and that reliance influenced their choice. A 2021 study in the Journal of Surgical Research interviewed specialists and women over 70 who had declined surgery. The two groups disagreed about how much family support the women had.
A Dutch study in BMC Geriatrics, published in November 2025, interviewed 16 relatives of patients aged 70 and over with cancer. Some described a dilemma between trusting doctors and trusting their own judgement. "I had my doubts about whether the doctor's recommendation for major surgery was in my husband's best interest," one patient's spouse said.
A 2022 study in the European Journal of Surgical Oncology found signs of age bias among UK breast cancer specialists. It tested their implicit attitudes and asked how they would treat sample patients. They held negative implicit associations towards older women and were less likely to recommend surgery for them. Some assumed older patients were more fearful, or less able to take part in decisions or cope with a poor prognosis.
A national audit covered women diagnosed in NHS hospitals in England and Wales between 2014 and 2016. It found that 76% of women aged 70 and over had surgery, against 96% of those aged 50 to 69. The audit's lead surgeon, Professor Kieran Horgan, said "all women should be offered treatment that is tailored to their type of tumour". His words appeared in the Royal College of Surgeons of England's release on the findings.
What guidelines say
The European Society of Breast Cancer Specialists and the International Society of Geriatric Oncology issued joint recommendations in The Lancet Oncology in 2021. The paper states that "decision making should not be driven by age alone but should involve geriatric assessments". It also calls for careful consideration of life expectancy, competing risks of death and patient preferences.
NICE, which sets guidance for England, recommends surgery plus drug treatment for oestrogen-sensitive invasive breast cancer. Its early and locally advanced breast cancer guideline advises against endocrine therapy alone "unless a significant comorbidity means surgery is not suitable".
The UK charity Breast Cancer Now has published standards of care for older adults, reviewed in June 2026. They call for treatment "based on overall health, not age alone". Each woman's priorities, health, medicines, nutrition and social needs should be assessed.
Who does well on tablets alone
In the new review, some tumours were more likely to respond to tablets for a long time. They had high oestrogen receptor levels, low grade, small size and low Ki-67, a marker of how fast cells divide. In groups selected for strong oestrogen sensitivity and treated with aromatase inhibitors, time to progression exceeded 50 months.
Higher frailty, more comorbidities and older age were linked to shorter survival, mainly through deaths from other causes. The authors propose combining tumour biology with frailty assessment to guide the choice, though that framework still needs testing in new studies.
The six trials included only 813 women, mostly treated in the tamoxifen era, and four did not report hazard ratios directly. Differences in health between groups made the observational studies unsuitable for pooling survival data. The review was not registered in advance, and earlier reviews, including one by Cochrane, have covered the same question.
What older women can ask
A woman offered tablets or surgery can ask her breast team about her tumour's biology. That includes its grade and how strongly it responds to oestrogen. She can ask whether she has had a geriatric or frailty assessment, and what it showed. If surgery is suggested, she can ask whether removing only the lump is possible, and what recovery will involve.
If tablets are suggested, she can ask how the tumour will be checked and what happens if it starts to grow. Surgery may still be possible later, as it was for many women in the earlier trials. Each woman can also say what is most important to her. For some, it is the longest possible control of the cancer, and for others the least disruption to daily life.
In the UK, Breast Cancer Now runs a free helpline on 0808 800 6000. Elsewhere, a breast care nurse or cancer specialist can point to local support services.
This content is for information only and does not replace advice from a qualified health professional.
Header image: Photo by Zoshua Colah on Unsplash

